相关实验视频

Updated: Jul 10, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

开发一种由亡细胞启发的抗体-药物联合体,用于有效的免疫调节

Gyeongwoo Lee^1,2, Taishu Iwase^1,2, Shunsuke Matsumoto^1,2

¹Research Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba 305-0044, Japan.

International journal of molecular sciences

|November 25, 2023

概括

这项研究引入了一种新型抗体-药物结合物 (ADC),其灵感来源于亡细胞,以减少炎症. 开发的ADC有效地准和抑制免疫反应,为抗炎疗法提供了一种新的方法.

科学领域:

生物材料科学生物材料科学
免疫学免疫学免疫学
药物输送系统药物输送系统

背景情况:

亡细胞具有免疫抑制的素 (PS) 组,可以抑制促炎信号.
PS组与免疫细胞 (如巨细胞,树突细胞和CD4+ T细胞) 相互作用.
之前的研究证实了PS固定聚合物的免疫调节作用,但它们在向抗炎抗体-药物联合体 (ADC) 中的使用尚未被探索.

研究的目的:

开发一种创新的抗体-药物联合体 (ADC),模仿亡细胞特性,用于向免疫调节.
调查素 (PS) 组作为ADC中抗炎应用中的有效载荷的潜力.

主要方法:

通过RAFT聚合作为ADC有效载荷,合成聚2-基乙基甲酸盐-co-2-甲基基乙基酸) (p(HEMA-co-MPS)) 通过RAFT聚合.
使用EDC/NHS化学,将p ((HEMA-co-MPS) 与山羊抗小鼠IgG结合在一起.
评估合成ADCs的抗体结合亲和力,抗炎功效和细胞毒性.

主要成果:

成功合成抗体-药物联合体 (ADCs),显示出显著的抗炎作用.
优化抗体-聚合物比率以最大限度地提高抗体结合亲和力.
在结合后,抗炎潜能和准能力的保留已被证明.

结论:

成功地将p ((HEMA-co-MPS) 纳入IgG,而不会影响抗炎性质或向能力.
强调优化抗体-聚合物比对治疗疗效的重要性.
建议在先进疗法中使用治疗抗体 (如托西利祖马布或阿巴塔塞普特) 的潜在应用.

关键词:

抗体药物联合体抗体药物联合体抗体聚合物合物生物灵感聚合物聚合物免疫调节的免疫调节

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...